# Large animal platform

- Animal models across multiple species, including NHP, mini-pig, dog, and rabbit
- Covering healthy animals, disease models, and animal biobank
- Evaluation of various therapeutic modalities
- Highly experienced team

### State-of-the-art large animal facility

**Chengdu & Nantong** including **ABSL-2 and BSL-2**

### Diverse animal species

**NHP (Cynomolgus, Rhesus), Minipig, Dog, Cat, Rabbit**

### Robust and reliable animal supply chain

Company-owned facilities for **NHP breeding and supplying**

### High-quality services

**One-stop** service platform, experienced team providing customized solutions

## Large animal disease models

### Diverse disease models

- **CNS:** Parkinson's disease, Stroke, Sleep disturbance, etc
- **Cardiovascular Disease:** Hypertension, Heart failure, Myocardial infarction, etc
- **Metabolic Disease:** Obesity, Diabetes, NASH, etc
- **Respiratory Disease:** Pulmonary artery hypertension, asthma, pulmonary fibrosis, etc
- **Autoimmune & Inflammatory disease:** Psoriasis, Ulcerative colitis, Dermatitis, etc
- **Hearing & Vision:** Hearing loss, Dry eyes, conjunctivitis, etc
- **Others:** Skin Scar, Osteoporosis, Urinary incontinence, etc

Cytokine therapeutics

Small molecule

Vaccine (mRNA & peptide)

Oligonucleotide (ASO & siRNA)

AAV

Ab & ADC & Bi-specific

Evaluation of different drug modalities

## Druggability assessment

**Clinical test, Bio-distribution, DRF/MTD, PD/Efficacy, Immunogenicity**

- **Clinical test:** Hematology profiling
- **Large animal pathological service:** Board certified pathologist
- **PD and NHP based Immune profiling:** Tissue cytometry, Nanostring, RNA scope
- **Immunogenicity:** ADA, Cytokine release
- **Clinical test:** Hematology profiling

**Multidisciplinary read-outs**
- Medical imaging
  — Endoscopy  — MRI  — X Ray
- Clinical & pathology scoring
- Skilled surgical procedures

ONCO WuXi

# Case study: AAV therapy efficacy in NHP Parkinson's disease model - ICV injection



(A) Changes of clinical scores to show the general behavior. (B) Changes of daily activity to show the potential akinesia changes. (C-D) Changes of the successful rate and the movement times in the food-retrieval task performance to show the hand movement capabilities.(E) PET-CT imaging with F18-dopa to show changes of the dopamine metabolism pre- and post- therapy.

# Case study: Post-life laboratory services



(A) NHP 21-colors flow panel with T, B, NK, monocyte, DC, and A MDSC cell subsets. (B) NHP single-cell processing of multiple tissues, including peripheral blood, liver, spleen, lymph node, lung, kidney, heart, skin, intestines, bone marrow, etc. (C) Statistics of cell viability after single-cell treatment of different tissues, the single-cell viability after tissue digestion was above 60% in all cases. (D) Analysis of the percentage of infiltrated or resident lymphocyte cells in different tissues.